Brief: Karyopharm Reports Prelim Unaudited 2023 Revenue And 2024 Objectives

Karyopharm Therapeutics

08/01/2024 17:41

Jan 8 (Reuters) - Karyopharm Therapeutics Inc  KPTI.O :
    * KARYOPHARM ANNOUNCES PRELIMINARY UNAUDITED 2023 REVENUE
AND 2024
OBJECTIVES
    * KARYOPHARM THERAPEUTICS INC: EXPECT CASH RUNWAY INTO LATE
2025
SUPPORTING COMPANY THROUGH MULTIPLE POTENTIALLY VALUE GENERATING
MILESTONES
    * KARYOPHARM THERAPEUTICS INC: EXPECTS TOTAL REVENUE, WHICH
INCLUDES LICENSE AND ROYALTY REVENUE FROM PARTNERS, TO BE ABOUT
$33.6 MILLION FOR Q4 2023
    * KARYOPHARM THERAPEUTICS INC: EXPECTS TOTAL REVENUE OF
ABOUT
$145.9 MILLION FOR FULL YEAR 2023
    * KARYOPHARM THERAPEUTICS INC:  EXPECTS U.S. XPOVIO NET
PRODUCT
REVENUE TO BE ABOUT $25.0 MILLION FOR Q4 2023 AND ABOUT $112.0
MILLION FOR FY 2023
    * KARYOPHARM THERAPEUTICS : TO OPTIMIZE COST STRUCTURE WITH
ABOUT
20% REDUCTION OF WORKFORCE, INCLUDING FULL-TIME EMPLOYEES &
CONTRACTORS

Source text for Eikon:  ID:nPn4z3VF4a 
Further company coverage:  KPTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))